Salicylic Acid in Novel Delivery System Delivers Potent Help for Hyperkeratotic Skin Disorders
NEW YORK, July 12, 2005--Dermatologists looking to treat chronic plaque psoriasis and localized hyperkeratotic skin disorders such as heel hyperkeratosis are finding that the patented delivery system available in SalexT (6% salicylic acid) Cream is providing significant benefit to their patients.
An open observational trial was initiated at two dermatology offices and included patients who were being treated for chronic plaque psoriasis vulgaris, localized hyperkeratosis on the palms, heels, elbows and soles, and keratosis pilaris. A total of 70 adult patients (ages 18-68) were included in an evaluation of once-daily treatment with Salex Cream1.
"A necessary goal of treatment for hyperkeratotic skin disorders has to be repair of epidermal barrier function," said James Q. Del Rosso, D.O., F.A.O.C.D., clinical assistant professor of dermatology at University of Nevada School of Medicine, chief investigator in the trial, and member of the Coria Laboratories Advisory Board. "Using a product with a novel delivery mechanism can greatly enhance the quality of treatment for these disorders. Salicylic acid is a good choice for treatment because a major mechanism of action of topical salicylic acid is reduction of corneocyte adhesion through disruption of corneodesmosomes. Salicylic acid does not induce alteration of keratin filaments."
The 6% salicylic acid cream used in the trial incorporates a patented new technology called MVE, or Multivesicular Emulsion. This technology allows for both the active and inert ingredients to be layered or stacked in the cream in such a way as to achieve a controlled, sustained release of all the ingredients over a period of time. Different actives may have varying release times. Even with 6% salicylic acid, Salex Cream with MVE technology was proven in a clinical study to be as non-irritating as the leading pediatric baby oil used as the control.
For plaque psoriasis, the addition of 6% salicylic acid cream to topical corticosteroid therapy resulted in 67% of patients being graded as at least "significantly improved" by investigator evaluation at eight weeks.
For localized hyperkeratosis (predominantly of plantar surfaces and heels), 69% and 82% of treated sites were rated by investigators to be at least "significantly improved" after four and eight weeks, respectively. Patients being treated for keratosis pilaris were also found by investigators to be at least "significantly improved" with 62% and 69% rated at four and eight weeks, respectively.
"Since patient compliance is always an issue," commented Dr. Del Rosso, "it is important to note that 100% of patients treated with 6% salicylic acid cream featuring MVE technology, reported that they would continue use of the product." Cosmetic acceptability parameters were rated as predominantly "excellent" or "very good."
Coria Laboratories, Ltd., formerly known as Healthpoint Dermatology Division, is a rapidly growing pharmaceutical company that specializes in research, development and marketing of branded prescription drugs and over-the-counter dermatology products. More information on Coria Laboratories and its products is available by calling 866.819.9007, or by visiting its website at www.corialabs.com
1 Del Rosso, JQ. Pharmacotherapy Update: The Many Uses of Topical Salicylic Acid. Skin & Aging 2005;13:38-42
# # #
From their website, Salex (6% salicylic acid) Cream and Lotion are indicated for the topical treatment of keratosis pilaris.
Has anyone been prescribed Salex for their keratosis pilaris?